Onderzoek naar aflevering van 124-I-F8IL10 in ontstoken gewrichten.
Recruiting
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NL-OMON28317
- Lead Sponsor
- VU University Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 5
Inclusion Criteria
1. Patients aged ≥18 years;
2. Diagnosis of RA according to ACR criteria;
Exclusion Criteria
1. Presence of active infections (e.g. requiring antibiotic therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study;
2. Chronic active hepatitis (hepatitis B/C) or active autoimmune diseases other than RA;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the targeting performance (including pharmacokinetics/-dynamics) of the human radiolabeled monoclonal-antibody cytokine fusion protein 124I-F8IL10 in 5 patients with rheumatoid arthritis, in a single dose study.
- Secondary Outcome Measures
Name Time Method To investigate dosimetric parameters of arthritic joints and internal organs.